Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 3/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149936 | 0.93 | GPR119 (0.34) | GPR119KCNH2NR1H2NR1H3SIGMAR1 | |
| SCHEMBL152372 | 0.87 | GPR119 (0.34) | GPR119KCNH2 | |
| SCHEMBL152137 | 0.85 | GPR119 (0.34) | GPR119KCNH2SLC6A9NR1H2NR1H3 | |
| SCHEMBL148491 | 0.81 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL121161 | 0.80 | DPP4 (0.39) | GPR119KCNH2HCRTR2 | |
| SCHEMBL148869 | 0.80 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL151876 | 0.80 | GPR119 (0.35) | GPR119KCNH2 | |
| SCHEMBL152099 | 0.80 | GPR119 (0.43) | GPR119KCNH2 | |
| SCHEMBL148008 | 0.79 | GPR119 (0.41) | GPR119KCNH2 | |
| SCHEMBL149154 | 0.78 | GPR119 (0.43) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | claimed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885KCNH2 2010/4885SLC6A9 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.